What a conventional LIMS report leaves out
- No connection drawn between detected genes and the organisms that carry them.
- Intrinsic resistance left for the reader to recall.
- Agents listed regardless of specimen site.
- Diagnosis coding handled somewhere else, later — often after the denial.
- A layout that looks like every other lab's.
Where CORE-ABR fits
CORE-ABR does not replace your LIMS. It takes the molecular panel result your laboratory already produces and builds the interpreted report from it — the antibiogram, the therapy scenarios, the quantification and the coding check — then delivers it by eFax to the ordering provider.
- Runs locally. The engine runs on your laboratory's infrastructure. Patient data doesn't have to leave the building.
- Configured to your panel. Organism targets, resistance genes, specimen types and site rules are mapped to the assay you actually run during setup.
- White labeled. Your logo, colors, laboratory name and director on every page.
- Coding checked before release. Samples submitted without a supporting ICD-10 code are caught at accessioning, not at appeal.
Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.